These medications must be used alongside reduced-calorie diet and increased physical activity as part of a comprehensive weight management program
Food and Drug Administration (FDA) has now approved two oral GLP-1 drugs: an oral version of Novo Nordisks Wegovy at the end of 2025, and Eli Lillys daily, non-peptide pillorforglipron, a distinct competitor to oral semaglutide and different from Eli Lillys injectable tirzepatidecalled Foundayo in April, which is notable because it can be taken without restrictions on timing or food or water intake
You may still prescribe compounded GLP-1 drugs in certain circumstances, but your prescription must clearly articulate a medically necessary and significant difference from the commercially available drug product
Semaglutide has been tested in several robust clinical development programs and outcome studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, liver disease and other related cardiometabolic diseases
For some, the nausea is mild and goes away after a few days or weeks
